Moleculin Biotech, Inc. (MBRX) · Nov 4, 2026 · Other events
Above the bar — CR 43%/36% vs 12% placebo
Moleculin’s clinical-trial update shows sharply higher interim AML remission rates and no observed cardiotoxicity, but the pivotal readout is still ahead.
Moleculin remains a clinical-stage biotech whose central value rests on Annamycin’s pivotal MIRACLE trial in relapsed/refractory AML. Part A enrollment was already completed in late September, with the company targeting a broader Q1 2027 data readout, so this filing adds interim detail rather than introducing a new development path.
| Measure | First 45 patients | Placebo |
|---|---|---|
| Complete remission — Annamycin arm 1 (Financial Highlights) | 43% | 12% |
| Complete remission — Annamycin arm 2 (Financial Highlights) | 36% | 12% |
The efficacy signal is clearly better than the control arm, but it is not wholly new. The first interim analysis showed complete remission rates of 43% and 36% for the two Annamycin arms versus 12% for placebo, a large treatment-control gap in the first 45 randomized patients. 〔0〕 Earlier company updates had already disclosed a positive interim efficacy signal, making the direction expected; the exact arm-level rates and formal presentation at ASH are the incremental news.
Safety remains supportive, but still provisional. No signs, symptoms, or echocardiographic findings suggestive of cardiotoxicity were observed through the cutoff, which reinforces Annamycin’s central differentiation from conventional anthracyclines. 〔1〕 However, the filing says the cardiac data still require independent expert and Data Monitoring Committee review at the second interim analysis, so this is evidence—not a final safety conclusion.
The trial is advancing without a setback, not accelerating to approval. The independent Data Monitoring Committee recommended continuing all three arms without amendment, which removes an immediate concern but does not establish statistical success or secure an NDA. 〔2〕 The next major evidence point remains the second interim analysis expected in early 2027. 〔3〕 The company also acknowledges that significant additional financing is required to complete the clinical program, leaving execution and funding as unresolved parts of the story.
Bottom line: This strengthens an already-positive Annamycin efficacy narrative with a sizeable treatment-control gap and continued cardiac-safety support. It is modestly positive rather than transformational because the signal was partly known, the dataset is small, and the decisive larger readout remains ahead.
ASH presentation, December 12-15, 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!